GRAIL

Overview

GRAIL, LLC operates within the government and research sectors, focusing on advancing the field of cancer screening and diagnostics. Based in Menlo Park, California, the company employs approximately 1,000 individuals and reported a revenue of $126 million. GRAIL's published research emphasizes the economic evaluations of cancer screening tests in the United States, highlighting their role in improving life expectancy and providing economic value, particularly for higher-risk populations. The company’s systematic literature review, presented at the ISPOR 2024 conference, details various cancer screening methodologies, including mammography, colonoscopy, and low-dose computed tomography, among others. This research underscores GRAIL's commitment to enhancing cancer detection and treatment strategies through rigorous analysis and evidence-based approaches. The focus on cancer screening reflects GRAIL's expertise in the biotech and pharmaceuticals industry, contributing to the broader discourse on health outcomes and economic implications of cancer care.

Industry